Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 147Leukemia, Lymphocytic, Chronic, B-Cell 140Lymphoma 116Lymphoma, Non-Hodgkin 112Leukemia, Myeloid, Acute 95Leukemia 92Myelodysplastic Syndromes 90Hodgkin Disease 68Lymphoma, B-Cell 61Leukemia, Myelogenous, Chronic, BCR-ABL Positive 53Multiple Myeloma 52Lymphoma, Mantle-Cell 52Lymphoma, Large B-Cell, Diffuse 50Lymphoma, Follicular 50Recurrence 43Burkitt Lymphoma 41Hematologic Neoplasms 36Myeloproliferative Disorders 31Lymphoma, B-Cell, Marginal Zone 30Neoplasms, Plasma Cell 20Primary Myelofibrosis 19Leukemia, Biphenotypic, Acute 18Anemia, Refractory, with Excess of Blasts 18Lymphoma, T-Cell 17Leukemia, Myelomonocytic, Chronic 15Graft vs Host Disease 15Anemia, Aplastic 15Leukemia, Prolymphocytic 14Neoplasms 12Leukemia, B-Cell 12

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Disease Attributes × fludarabine × Lymphoid × Clear all
NCT05826535 2026-05-28

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Lyell Immunopharma, Inc.

Phase 1/2 Recruiting
270 enrolled
Lymphoid

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡